Merck to Present New Data for KEYTRUDA ® (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting

< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Data Evaluating KEYTRUDA as a Single Agent and in Novel Combinations Across a Wide Range of Cancers to Be Presented < /p > < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new research investigating the use of KEYTRUDA < sup > ® < /sup >
(pembrolizumab), the company ’s anti-PD-1 therapy, in multiple tumor
types, both as a single agent and in combination with other therapies,
will be presented at this year’s American Association for Cancer
Research (AACR) Annual Meeting in New Orleans, April 16 – 20. < /p > < div class= " field field-type-text field-field-press-release-language field-fieldpressreleaselanguage " > < div class= " field-label " > Language: < /div > < div class= " field-items " > < div class= " field-item odd " >
English < /div > < /div > < /div...

Source: Merck.com - Research and Development News - April 6, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK AACR Keytruda NYSE:MRK Source Type: news